|
1
|
Richard S, Gardie B, Couvé S and Gad S:
Von Hippel-Lindau: How a rare disease illuminates cancer biology.
Semin Cancer Biol. 23:26–37. 2013. View Article : Google Scholar
|
|
2
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sato Y, Yoshizato T, Shiraishi Y, Maekawa
S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki
H, et al: Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu P, Liu JL, Pei SM, Wu CP, Yang K, Wang
SP and Wu S: Integrated genomic analysis identifies clinically
relevant subtypes of renal clear cell carcinoma. BMC Cancer.
18:2872018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiesen HJ, Steinbeck F, Maruschke M,
Koczan D, Ziems B and Hakenberg OW: Stratification of clear cell
renal cell carcinoma (ccRCC) genomes by gene-directed copy number
alteration (CNA) analysis. PLoS One. 12:e01766592017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gerlinger M, Horswell S, Larkin J, Rowan
AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos
CR, et al: Genomic architecture and evolution of clear cell renal
cell carcinomas defined by multiregion sequencing. Nat Genet.
46:225–233. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas and Research Network:
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar
|
|
8
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz
KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et
al: Patterns of gene expression and copy-number alterations in
von-hippel lindau disease-associated and sporadic clear cell
carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shuib S, Wei W, Sur H, Morris MR, McMullan
D, Rattenberry E, Meyer E, Maxwell PH, Kishida T, Yao M, et al:
Copy number profiling in von Hippel-Lindau disease renal cell
carcinoma. Genes Chromosomes Cancer. 50:479–488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fisher R, Horswell S, Rowan A, Salm MP, de
Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I,
et al: Development of synchronous VHL syndrome tumors reveals
contingencies and constraints to tumor evolution. Genome Biol.
15:4332014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV and Croce CM: Causes and
consequences of microRNA dysregulation. Cancer J. 18:215–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar
|
|
15
|
Neal CS, Michael MZ, Rawlings LH, Van der
Hoek MB and Gleadle JM: The VHL-dependent regulation of microRNAs
in renal cancer. BMC Med. 8:642010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Messai Y, Gad S, Noman MZ, Le Teuff G,
Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot
S, et al: Renal cell carcinoma programmed death-ligand 1, a new
direct target of hypoxia-inducible factor-2 alpha, is regulated by
von Hippel-Lindau gene mutation status. Eur Urol. 70:623–632. 2016.
View Article : Google Scholar
|
|
17
|
Gentleman RC, Carey VJ, Bates DM, Bolstad
B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al:
Bioconductor: Open software development for computational biology
and bioinformatics. Genome Biol. 5:R802004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Silva-Santos RM, Costa-Pinheiro P, Luis A,
Antunes L, Lobo F, Oliveira J, Henrique R and Jerónimo C: MicroRNA
profile: A promising ancillary tool for accurate renal cell tumour
diagnosis. Br J Cancer. 109:2646–2653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Christinat Y and Krek W: Integrated
genomic analysis identifies subclasses and prognosis signatures of
kidney cancer. Oncotarget. 6:10521–10531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gowrishankar B, Ibragimova I, Zhou Y,
Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG and Cairns P:
MicroRNA expression signatures of stage, grade, and progression in
clear cell RCC. Cancer Biol Ther. 15:329–341. 2014. View Article : Google Scholar :
|
|
22
|
Miko E, Czimmerer Z, Csánky E, Boros G,
Buslig J, Dezso B and Scholtz B: Differentially expressed microRNAs
in small cell lung cancer. Exp Lung Res. 35:646–664. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chan SY and Loscalzo J: MicroRNA-210: A
unique and pleiotropic hypoxamir. Cell Cycle. 9:1072–1083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Puisségur MP, Mazure NM, Bertero T,
Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K,
Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late
stages of lung cancer and mediates mitochondrial alterations
associated with modulation of HIF-1 activity. Cell Death Differ.
18:465–478. 2011. View Article : Google Scholar :
|
|
25
|
Couvé S, Ladroue C, Laine E, Mahtouk K,
Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, et al:
Genetic evidence of a precisely tuned dysregulation in the hypoxia
signaling pathway during oncogenesis. Cancer Res. 74:6554–6564.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kulshreshtha R, Davuluri RV, Calin GA and
Ivan M: A microRNA component of the hypoxic response. Cell Death
Differ. 15:667–671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen D, Cabay RJ, Jin Y, Wang A, Lu Y,
Shah-Khan M and Zhou X: MicroRNA deregulations in head and neck
squamous cell carcinomas. J Oral Maxillofac Res. 4:e22013.
View Article : Google Scholar
|
|
28
|
Kong W, He L, Richards EJ, Challa S, Xu
CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, et
al: Upregulation of miRNA-155 promotes tumour angiogenesis by
targeting VHL and is associated with poor prognosis and
triple-negative breast cancer. Oncogene. 33:679–689. 2014.
View Article : Google Scholar :
|
|
29
|
Bruning U, Cerone L, Neufeld Z,
Fitzpatrick SF, Cheong A, Scholz CC, Simpson DA, Leonard MO,
Tambuwala MM, Cummins EP, et al: MicroRNA-155 promotes resolution
of hypoxia-inducible factor 1alpha activity during prolonged
hypoxia. Mol Cell Biol. 31:4087–4096. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hell MP, Thoma CR, Fankhauser N,
Christinat Y, Weber TC and Krek W: miR-28-5p promotes chromosomal
instability in VHL-associated cancers by inhibiting Mad2
translation. Cancer Res. 74:2432–2443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mathew LK, Lee SS, Skuli N, Rao S, Keith
B, Nathanson KL, Lal P and Simon MC: Restricted expression of
miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas
enhances HIF2α activity. Cancer Discov. 4:53–60. 2014. View Article : Google Scholar
|
|
32
|
Favier J, Brière JJ, Burnichon N, Rivière
J, Vescovo L, Benit P, Giscos-Douriez I, De Reyniès A, Bertherat J,
Badoual C, et al: The Warburg effect is genetically determined in
inherited pheochromocytomas. PLoS One. 4:e70942009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mullen AR, Wheaton WW, Jin ES, Chen PH,
Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS and
DeBerardinis RJ: Reductive carboxylation supports growth in tumour
cells with defective mitochondria. Nature. 481:385–388. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmidt LS and Linehan WM: Genetic
predisposition to kidney cancer. Semin Oncol. 43:566–574. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Elsässer-Beile U, Grussenmeyer T,
Gierschner D, Schmoll B, Schultze-Seemann W, Wetterauer U and
Schulte Mönting J: Semiquantitative analysis of Th1 and Th2
cytokine expression in CD3+, CD4+, and
CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Cancer Immunol Immunother. 48:204–208. 1999. View Article : Google Scholar
|
|
36
|
Finke JH, Rayman P, Edinger M, Tubbs RR,
Stanley J, Klein E and Bukowski R: Characterization of a human
renal cell carcinoma specific cytotoxic CD8+ T cell
line. J Immunother. 1991(11): 1–11. 1992. View Article : Google Scholar
|
|
37
|
Gaudin C, Dietrich PY, Robache S, Guillard
M, Escudier B, Lacombe MJ, Kumar A, Triebel F and Caignard A: In
vivo local expansion of clonal T cell subpopulations in renal cell
carcinoma. Cancer Res. 55:685–690. 1995.PubMed/NCBI
|
|
38
|
Schwaab T, Schned AR, Heaney JA, Cole BF,
Atzpodien J, Wittke F and Ernstoff MS: In vivo description of
dendritic cells in human renal cell carcinoma. J Urol. 162:567–573.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zagzag D, Krishnamachary B, Yee H, Okuyama
H, Chiriboga L, Ali MA, Melamed J and Semenza GL: Stromal
cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma
and clear cell-renal cell carcinoma: Von Hippel-Lindau
loss-of-function induces expression of a ligand and its receptor.
Cancer Res. 65:6178–6188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Altuvia Y, Landgraf P, Lithwick G, Elefant
N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T and Margalit H:
Clustering and conservation patterns of human microRNAs. Nucleic
Acids Res. 33:2697–2706. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yuan X, Liu C, Yang P, He S, Liao Q, Kang
S and Zhao Y: Clustered microRNAs' coordination in regulating
protein-protein interaction network. BMC Syst Biol. 3:652009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kawakami T, Chano T, Minami K, Okabe H,
Okada Y and Okamoto K: Imprinted DLK1 is a putative tumor
suppressor gene and inactivated by epimutation at the region
upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet.
15:821–830. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Thayanithy V, Sarver AL, Kartha RV, Li L,
Angstadt AY, Breen M, Steer CJ, Modiano JF and Subramanian S:
Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.
Bone. 50:171–181. 2012. View Article : Google Scholar
|
|
44
|
Gattolliat CH, Thomas L, Ciafrè SA,
Meurice G, Le Teuff G, Job B, Richon C, Combaret V, Dessen P,
Valteau-Couanet D, et al: Expression of miR-487b and miR-410
encoded by 14q32.31 locus is a prognostic marker in neuroblastoma.
Br J Cancer. 105:1352–1361. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gattolliat CH, Le Teuff G, Combaret V,
Mussard E, Valteau-Couanet D, Busson P, Bénard J and Douc-Rasy S:
Expression of two parental imprinted miRNAs improves the risk
stratification of neuroblastoma patients. Cancer Med. 3:998–1009.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang SW, Chang WH, Su YC, Chen YC, Lai YH,
Wu PT, Hsu CI, Lin WC, Lai MK and Lin JY: MYC pathway is activated
in clear cell renal cell carcinoma and essential for proliferation
of clear cell renal cell carcinoma cells. Cancer Lett. 273:35–43.
2009. View Article : Google Scholar
|
|
47
|
Liu Y, Zhang M, Qian J, Bao M, Meng X,
Zhang S, Zhang L, Zhao R, Li S, Cao Q, et al: miR-134 functions as
a tumor suppressor in cell proliferation and
epithelial-to-mesenchymal Transition by targeting KRAS in renal
cell carcinoma cells. DNA Cell Biol. 34:429–436. 2015. View Article : Google Scholar : PubMed/NCBI
|
